On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation
- 25 March 2015
- journal article
- review article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 7 (280), 280sr1
- https://doi.org/10.1126/scitranslmed.3010274
Abstract
This Review presents the state of research and future outlook on cancer immunotherapy approaches such as immune checkpoint inhibitors.Keywords
Funding Information
- American Cancer Society (MRSG-11-054-01-LIB)
- Ludwig Collaborative Laboratory
- Swim Across America
- Cycle for Survival
This publication has 101 references indexed in Scilit:
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Immunologic Correlates of the Abscopal Effect in a Patient with MelanomaNew England Journal of Medicine, 2012
- Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumabProceedings of the National Academy of Sciences, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel ImmunotherapySeminars in Oncology, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences, 2010
- Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use settingCancer, 2010
- CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefitProceedings of the National Academy of Sciences, 2008